VRDN Viridian Therapeutics, Inc.\DE
Nasdaq · SEC CIK 1590750 · EDGAR
- Bought, last 12 months
- $30.00M 2 purchases by 2 insiders
- Sold, last 12 months
- $419.0K 2 sales by 1 insiders
- Filings on record
- 93 since 2021-07-15, latest 2026-08-20 20:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Fairmount Funds Management LLC | Dir, 10% | $20.00M | — |
| Fairmount Healthcare Fund II GP LLC | Dir, 10% | $10.00M | — |
| Tousignant Jennifer | CLO | — | $419.0K |
| Harmon Seth | CFO | — | — |
| Tripuraneni Radhika | Chief Medical Off | — | — |
| Mahoney Stephen F. | Pres, CEO, Dir | — | — |
| Beetham Thomas W. | COO | — | — |
Transactions 58
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-20 20:05 | 2026-08-19 | VRDN | Tousignant Jennifer | CLO | S - Sale+OE | $24.50 | -14.2K | 0 | -100% | -$348.2K |
| D | 2026-08-20 20:05 | 2026-08-19 | VRDN | Tousignant Jennifer | CLO | M - OptEx | $14.41 | +10.0K | 10.0K | New | +$144.1K |
| D | 2026-08-18 17:34 | 2026-08-14 | VRDN | Tripuraneni Radhika | Chief Medical Off | M - OptEx | $13.21 | +40.0K | 40.0K | New | +$528.4K |
| I | 2026-05-13 16:31 | 2026-05-11 | VRDN | Fairmount Funds Management LLC | Dir, 10% | P - Purchase | $17.00 | +1.18M | 5.09M | +30% | +$20.00M |
| A | 2026-03-09 | 2026-03-03 | VRDN | Mahoney Stephen F. | Pres, CEO, Dir | F - Tax | $30.19 | -7,408 | 33.3K | -18% | -$223.6K |
| A | 2026-03-09 | 2026-03-03 | VRDN | Tousignant Jennifer | CLO | F - Tax | $30.19 | -1,675 | 3,494 | -32% | -$50.6K |
| A | 2026-03-09 | 2026-03-03 | VRDN | Beetham Thomas W. | COO | F - Tax | $30.19 | -3,048 | 13.4K | -19% | -$92.0K |
| A | 2026-03-09 | 2026-03-03 | VRDN | Harmon Seth | CFO | F - Tax | $30.19 | -2,031 | 7,850 | -21% | -$61.3K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Tousignant Jennifer | CLO | M - OptEx | — | +5,169 | 5,169 | New | — |
| D | 2026-03-04 | 2026-03-03 | VRDN | Tousignant Jennifer | CLO | F - Tax | $29.32 | -1,724 | 3,445 | -33% | -$50.5K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Harmon Seth | CFO | M - OptEx | — | +6,267 | 9,881 | +173% | — |
| D | 2026-03-04 | 2026-03-03 | VRDN | Harmon Seth | CFO | F - Tax | $29.32 | -2,091 | 7,790 | -21% | -$61.3K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Mahoney Stephen F. | Pres, CEO | F - Tax | $29.32 | -7,627 | 33.1K | -19% | -$223.6K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Mahoney Stephen F. | Pres, CEO | M - OptEx | — | +18.4K | 40.8K | +82% | — |
| D | 2026-03-04 | 2026-03-03 | VRDN | Beetham Thomas W. | COO | M - OptEx | — | +9,409 | 16.4K | +134% | — |
| D | 2026-03-04 | 2026-03-03 | VRDN | Beetham Thomas W. | COO | F - Tax | $29.32 | -3,138 | 13.3K | -19% | -$92.0K |
| 2026-01-02 | 2025-12-31 | VRDN | Tousignant Jennifer | CLO | S - Sale | $31.16 | -2,272 | 0 | -100% | -$70.8K | |
| I | 2025-10-27 | 2025-10-23 | VRDN | Fairmount Healthcare Fund II GP LLC | Dir, 10% | P - Purchase | $22.00 | +454.5K | 3.91M | +13% | +$10.00M |
| DMI | 2025-06-11 | 2025-06-09+ | VRDN | Fairmount Funds Management LLC | Dir, 10% | M - OptEx | $11.80 | +14.1K | 3.46M | +0.4% | +$166.4K |
| 2024-09-30 | 2024-09-27 | VRDN | Beetham Thomas W. | COO | P - Purchase | $23.41 | +5,000 | 6,000 | +500% | +$117.0K | |
| 2024-09-30 | 2024-09-27 | VRDN | Mahoney Stephen F. | Pres, CEO, Dir | P - Purchase | $23.33 | +21.4K | 21.4K | New | +$499.3K | |
| I | 2024-09-17 | 2024-09-13 | VRDN | Fairmount Healthcare Fund II L.P. | Dir, 10% | P - Purchase | $18.75 | +1.60M | 3.45M | +87% | +$30.00M |
| DMI | 2024-04-01 | 2024-03-28 | VRDN | Fairmount Healthcare Fund II L.P. | Dir, 10% | J - Other | — | 0 | 1.85M | New | — |
| I | 2024-01-24 | 2024-01-22 | VRDN | Fairmount Healthcare Fund II L.P. | Dir, 10%, See Remarks | P - Purchase | $21.00 | +476.2K | 1.84M | +35% | +$10.00M |
| DM | 2023-06-20 | 2023-06-15+ | VRDN | Meisner Lara | CLO | S - Sale+OE | $28.02 | -2,296 | 30.0K | -7% | -$64.3K |
| DM | 2023-06-20 | 2023-06-15+ | VRDN | Meisner Lara | CLO | M - OptEx | $23.03 | +2,296 | 30.0K | +8% | +$52.9K |
| DM | 2023-06-06 | 2023-06-02+ | VRDN | Meisner Lara | CLO | M - OptEx | $17.38 | +7,500 | 30.5K | +33% | +$130.4K |
| DM | 2023-06-06 | 2023-06-02+ | VRDN | Meisner Lara | CLO | S - Sale+OE | $24.82 | -7,500 | 30.0K | -20% | -$186.1K |
| 2023-04-12 | 2023-04-12 | VRDN | Myers Scott Dunseth | CEO, Dir | P - Purchase | $25.37 | +4,000 | 259.5K | +2% | +$101.5K | |
| 2023-03-13 | 2023-03-13 | VRDN | Myers Scott Dunseth | CEO, Dir | P - Purchase | $29.15 | +5,500 | 255.5K | +2% | +$160.3K | |
| 2023-03-10 | 2023-03-09 | VRDN | Meisner Lara | GC, Sec | S - Sale | $29.07 | -30.0K | 0 | -100% | -$871.3K | |
| DA | 2023-02-07 | 2023-02-02 | VRDN | Violin Jonathan | CEO, Dir | S - Sale+OE | $36.80 | -50.0K | 480.9K | -9% | -$1.84M |
| DA | 2023-02-07 | 2023-02-02 | VRDN | Violin Jonathan | CEO, Dir | M - OptEx | $0.15 | +50.0K | 530.9K | +10% | +$7,500 |
| D | 2023-02-07 | 2023-02-06 | VRDN | Myers Scott Dunseth | CEO, Dir | A - Grant | $0.00 | +250.0K | 250.0K | New | $0 |
| 2023-02-03 | 2023-02-02 | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $36.80 | -50.0K | 430.9K | -10% | -$1.84M | |
| DM | 2023-01-25 | 2023-01-23 | VRDN | Meisner Lara | GC, Sec | M - OptEx | $20.56 | +6,843 | 6,843 | New | +$140.7K |
| D | 2023-01-25 | 2023-01-23 | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $35.66 | -6,843 | 0 | -100% | -$244.0K |
| DM | 2023-01-18 | 2023-01-13+ | VRDN | Katz Barrett | Chief Medical Off | M - OptEx | $23.03 | +29.0K | 4,147 | New | +$667.9K |
| DM | 2023-01-18 | 2023-01-13+ | VRDN | Katz Barrett | Chief Medical Off | S - Sale+OE | $37.18 | -29.0K | 0 | -100% | -$1.08M |
| DM | 2023-01-11 | 2023-01-09+ | VRDN | Katz Barrett | Chief Medical Off | M - OptEx | $23.03 | +60.0K | 47.4K | New | +$1.38M |
| DM | 2023-01-11 | 2023-01-09+ | VRDN | Katz Barrett | Chief Medical Off | S - Sale+OE | $34.82 | -60.0K | 0 | -100% | -$2.09M |
| DM | 2022-12-22 | 2022-12-20+ | VRDN | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +16.9K | 16.3K | New | +$389.8K |
| DM | 2022-12-22 | 2022-12-20+ | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $29.15 | -16.9K | 0 | -100% | -$493.4K |
| DM | 2022-12-19 | 2022-12-15+ | VRDN | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +1,597 | 1,297 | New | +$36.8K |
| DM | 2022-12-19 | 2022-12-15+ | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $28.37 | -1,597 | 0 | -100% | -$45.3K |
| DM | 2022-12-14 | 2022-12-12+ | VRDN | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +16.3K | 600 | New | +$374.4K |
| DM | 2022-12-14 | 2022-12-12+ | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $28.12 | -16.3K | 0 | -100% | -$457.1K |
| D | 2022-11-16 | 2022-11-15 | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $22.05 | -8,125 | 0 | -100% | -$179.2K |
| D | 2022-11-16 | 2022-11-15 | VRDN | Meisner Lara | GC, Sec | M - OptEx | $14.00 | +8,125 | 8,125 | New | +$113.8K |
| I | 2022-08-19 | 2022-08-17 | VRDN | Fairmount Healthcare Fund GP LLC | Dir, 10% | P - Purchase | $23.50 | +425.5K | 1.36M | +45% | +$10.00M |
| 2022-06-02 | 2022-06-01 | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $12.20 | -30.0K | 480.9K | -6% | -$366.0K | |
| 2022-05-04 | 2022-05-02 | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $13.04 | -30.0K | 510.9K | -6% | -$391.2K | |
| M | 2022-04-05 | 2022-04-01+ | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $18.92 | -30.0K | 540.9K | -5% | -$567.6K |
| M | 2022-03-03 | 2022-03-01+ | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $17.65 | -30.0K | 582.0K | -5% | -$529.5K |
| DM | 2022-02-03 | 2022-02-01+ | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $19.09 | -30.0K | 600.9K | -5% | -$572.8K |
| D | 2021-12-10 | 2021-12-08 | VRDN | Violin Jonathan | See Remarks, Dir | C - Cnv Deriv | $0.00 | +627.6K | 630.9K | +18,784% | $0 |
| 2021-09-28 | 2021-09-23 | VRDN | Frazier Life Sciences Public Fund, L.P. | 10% | P - Purchase | $11.00 | +200.0K | 1.51M | +15% | +$2.20M | |
| I | 2021-09-23 | 2021-09-21 | VRDN | Fairmount Healthcare Fund L.P. | Dir, See Remarks | P - Purchase | $11.00 | +909.0K | 938.2K | +3,109% | +$10.00M |
Purchase Sale Sale after option exercise All abbreviations